ArticleScientific reports2025
A novel role for colistin as an efflux pump inhibitor in multidrug-resistant Klebsiella pneumoniae.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fosfomycin at sub-minimum inhibitory concentration impairs biofilm and efflux pump activity in multidrug-resistant Klebsiella pneumoniae isolates.BMC microbiology · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- The colistin resistance pandemic: A dual threat from plasmid-encoded mobilised colistin resistance genes and chromosomal mutations.African journal of laboratory medicine · 2026Review
- Intestinal mucus acts as a nutrient source and signal forMicrobiome research reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antimicrobial resistance (AMR) is a global challenge that demands new strategies to maintain the effectiveness of current treatments. AMR arises through various mechanisms, including overexpression of drug efflux pumps. The AcrAB-TolC efflux pump is used by Enterobacterales such as Klebsiella pneumoniae to expel antibiotics and overcome antimicrobial toxicity. Here we explored a novel secondary activity of colistin as an efflux pump inhibitor. Experiments were conducted to determine antimicrobial susceptibility, selection of a resistant mutant, assess the function of efflux machinery under various treatment conditions, and measure the inhibition of extrusion by colistin. Colistin augmented the efficacy of various antibiotics against resistant K. pneumoniae strains and reversed clinically relevant antibiotic resistance caused by acrAB overexpression. This effect was demonstrated via increased uptake of efflux pump substrates such as N-phenyl-1-napthylamine, ethidium bromide, and Hoechst dye in K. pneumoniae overexpressing the AcrAB efflux pump. Molecular docking models indicated that colistin likely binds to the transmembrane region of K. pneumoniae AcrB, further validating colistin’s function as an efflux pump inhibitor at low concentrations. Scanning electron microscopy showed that sub-nephrotoxic concentrations of colistin had no effect on bacterial membrane integrity. These novel findings highlight the therapeutic potential of sub-nephrotoxic concentrations of colistin as an adjuvant to overcome efflux-mediated resistance in clinically problematic Enterobacterales K. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.